Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR SIGNS CO-DEVELOPMENT AND EXCLUSIVE LICENCE OPTION AGREEMENT WITH LEADING GLOBAL MEDICAL PRODUCTS COMPANY FOR IN-HOUSE SPECIALITY HOSPITAL PRODUCT
Arecor-developed, Arestat™-enabled product is potentially first ready-to-dilute liquid formulation of a high-value oncology therapy
Cambridge, UK, 4 December 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces a co-development and exclusive licence option agreement with a leading global medical products…
Seasoned Life Sciences pharmaceutical physician and leader joins the region’s Life Science & Healthcare membership organisation
One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, is delighted to announce the appointment of Judit Molnar, a seasoned pharmaceutical physician and leader, with experience across large pharma and biotech. as a Non-Executive Director. Judit is VP and Head of Early Development, tranScrip, leading the Early Development Team, supporting clients with early development activities from pre-clinical stage…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR CONTINUES COLLABORATION WITH LILLY
Development of an enhanced formulation of Lilly proprietary product using Arecor’s formulation technology platform Arestat™
Cambridge, UK, 29 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with Eli Lilly and Company (“Lilly”).
Under the terms of this agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a…
Leading life sciences products and services provider - AMSBIO announce the launch of a custom service providing access to a suite of powerful spatial biology multi-omics profiling tools.
NanoString GeoMx DSP is a new flexible multi-omics platform that enables reliable quantitative assessment of the spatial heterogeneity within various sample types including FFPE, TMAs, and fresh-frozen tissue - with no prequalification required. Tackling the challenge of compromised sample data due to non-target tissue cells, NanoString GeoMx DSP integrates cutting-edge in situ visualization with molecular…
November 2023
Kadans Science Partner given green light for new purpose-built laboratory scheme in King’s Cross, London
London, November 29, 2023 - Kadans Science Partner (“Kadans”) has secured planning permission from the London Borough of Islington, for a new, purpose-built laboratory and office building in London’s Knowledge Quarter, King’s Cross. The new build development has been designed with a specialist professional team and the Kadans Science Partner inhouse development team. This investment represents the physical implementation of Kadans’ long-term model to bolster both specialist…
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesis
Refined focus on neurodegenerative disease targets
Proceeds to be used to advance lead programme targeting FAN1 nuclease in Huntington’s Disease towards the clinic
Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology…
Biocair, a leading specialist in cell and gene therapy logistics, is proud to announce its alliance with Pharma.Aero, a global cross-industry collaboration platform. Together, they are driving transformation in the cell and gene therapy (CGT) supply chain.
Cell and gene therapies are a revolutionary way to fight disease in that they offer patients complete personalization of medicine. These time-sensitive and life-changing medicines need logistics solutions as innovative as they are.
To ensure the supply chain is consistently improving, Pharma.Aero set up the Cell and Gene Therapies Project…
Source Genomics White Paper explores the transformative power of multi-omics in genomic research.
Multiomics combines the various ‘omics disciplines that make up the complex landscape of life science research. With the integration of genomic, transcriptomic, proteomic and epigenomic data, we obtain an advanced vision of the overarching framework behind all phenotypic outcomes.
This White Paper highlights the central role of multiomics in life science research, including its practical applications across diverse fields spanning cancer research, drug development and the ongoing journey…
AMSBIO has announced a new range of customizable ELISA assay kits designed to enable experienced researchers to achieve reliable and reproducible assay results.
With over 500 ELISA kits to choose from, the new range covers a wide variety of biological processes, targets, and sample types. Reagents such as matched antibody pairs and a micro-ELISA pre-plate have been carefully screened and validated to save you time and money.
By combining uncoated ELISA and Ancillary reagent kit with optimized and pre-titrated reagents, researchers can enhance the reliability of their ELISA assay development.…
Entire 11,000 sq ft next generation lab developed by Gen Two to become the British biotech company’s HQ
LONDON, 23 NOVEMBER 2023 – Constructive Bio
Constructive Bio, a visionary biotech company, is excited to announce their transformative growth and relocation to their new headquarters, 'The Recodery'. Since their establishment in 2022, backed by a £12.4 million seed investment, and under the leadership of their female CEO, Ola Wlodek, PhD EMBA and scientific guidance of professor Jason Chin as a CSO, the company now boasts a robust and growing team. Constructive Bio’s journey began in…